Observational single-center cohorts reported lower rates of rituximab use: 5/28 patients with anti-CASPR2 [8], 3/28 patients with anti-GAD65 [24], and 3/14 patients with anti-LGI1 encephalitis [20]. This evidence concerns the gene LGI1 and viral encephalitis.